Nissay Asset Management Corp Japan ADV increased its position in shares of Baxter International Inc (NYSE:BAX) by 13.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 125,013 shares of the medical instruments supplier’s stock after purchasing an additional 15,114 shares during the quarter. Nissay Asset Management Corp Japan ADV’s holdings in Baxter International were worth $9,231,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in shares of Baxter International by 3,088.9% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,435 shares of the medical instruments supplier’s stock worth $106,000 after purchasing an additional 1,390 shares during the period. Ostrum Asset Management acquired a new stake in shares of Baxter International during the first quarter worth about $121,000. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of Baxter International by 84.4% during the second quarter. Whittier Trust Co. of Nevada Inc. now owns 1,748 shares of the medical instruments supplier’s stock worth $126,000 after purchasing an additional 800 shares during the period. Vigilant Capital Management LLC acquired a new stake in shares of Baxter International during the second quarter worth about $131,000. Finally, IHT Wealth Management LLC lifted its holdings in shares of Baxter International by 71.9% during the first quarter. IHT Wealth Management LLC now owns 2,462 shares of the medical instruments supplier’s stock worth $156,000 after purchasing an additional 1,030 shares during the period. 82.92% of the stock is owned by hedge funds and other institutional investors.
Shares of NYSE:BAX opened at $71.25 on Thursday. Baxter International Inc has a 12-month low of $60.53 and a 12-month high of $76.51. The company has a market capitalization of $38.20 billion, a price-to-earnings ratio of 28.73, a P/E/G ratio of 1.79 and a beta of 0.77. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.62 and a quick ratio of 2.00.
The firm also recently announced a quarterly dividend, which will be paid on Monday, October 1st. Stockholders of record on Friday, August 31st will be paid a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a dividend yield of 1.07%. The ex-dividend date of this dividend is Thursday, August 30th. Baxter International’s payout ratio is 30.65%.
A number of brokerages have issued reports on BAX. Citigroup boosted their price target on Baxter International from $74.00 to $76.00 and gave the company a “neutral” rating in a report on Tuesday, July 31st. Zacks Investment Research raised Baxter International from a “hold” rating to a “buy” rating and set a $79.00 price target for the company in a report on Thursday, May 17th. Royal Bank of Canada reissued a “hold” rating and issued a $76.00 price target on shares of Baxter International in a report on Friday, July 27th. Stifel Nicolaus boosted their price target on Baxter International from $71.00 to $72.00 and gave the company a “hold” rating in a report on Monday, April 30th. Finally, Piper Jaffray Companies began coverage on Baxter International in a report on Thursday, May 17th. They issued an “overweight” rating and a $77.00 price target for the company. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $76.00.
In other news, Director Carole J. Shapazian sold 5,400 shares of the company’s stock in a transaction that occurred on Wednesday, August 8th. The stock was sold at an average price of $72.97, for a total transaction of $394,038.00. Following the completion of the transaction, the director now directly owns 15,248 shares of the company’s stock, valued at approximately $1,112,646.56. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Carole J. Shapazian sold 6,594 shares of the company’s stock in a transaction that occurred on Tuesday, May 22nd. The stock was sold at an average price of $71.79, for a total value of $473,383.26. Following the transaction, the director now directly owns 16,442 shares of the company’s stock, valued at $1,180,371.18. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 74,877 shares of company stock valued at $5,468,755. Corporate insiders own 0.07% of the company’s stock.
Baxter International Profile
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Featured Story: Penny Stocks, Risk and Reward Factors
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.